Effects of zinc and vitamin D separately and in combination on mood in overweight and obese subjects

Effects of zinc and vitamin D separately and in combination on mood, cortisol, tryptophan—kynurenine pathway, BDNF and hs-CRP in overweight and obese subjects

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201601252394N31

Enrollment

140

Registered

2016-10-31

Start date

2016-10-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obesity. Simple obesity NOS

Interventions

Intervention 1: vitamin D- 2000 IU /day for 12 week zinc- 30 mg/day for 12 week. Intervention 2: zinc Placebo- 30 mg/day for 12 week vitamin D Placebo- 2000 IU/day for 12 week. Intervention 3: vitamin

Treatment - Other

Placebo

Treatment - Drugs

vitamin D- 2000 IU /day for 12 week zinc- 30 mg/day for 12 week

zinc Placebo- 30 mg/day for 12 week vitamin D Placebo- 2000 IU/day for 12 week

vitamin D 2000 IU/day for 12 week and zinc placebo for 12 week

zinc 30 mg/day 12 week and vitamin D placebo for 12 week

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:age between 20 to 60 years old; BMI > 27; willing to participate; weight stable in 3 last months. Exclusion criteria: Having a history of coronary artery disease; acute or chronic renal failure; acute or chronic hepatic failure; presence of any chronic inflammatory and autoimmune disease; and any known malignancy; hormone therapy; Other non-pathological exclusion criteria included pregnancy; breast feeding; post-menopause; smoking, professional athlete; uncontrolled thyroid disorder; use of medications for dyslipidemia or hypertension; having a special diet for any reason prescribed by the clinic dietitian; consumption of nutritional supplements within the past 8 weeks.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Mood. Timepoint: At baseline and after weeks 12. Method of measurement: Beck Depression Inventory.;Serum cortisol. Timepoint: At baseline and after weeks 12. Method of measurement: ELISA.;Serum tryptophan. Timepoint: At baseline and after weeks 12. Method of measurement: ELISA.;Serum kynurenine. Timepoint: At baseline and after weeks 12. Method of measurement: ELISA.;Serum BDNF. Timepoint: At baseline and after weeks 12. Method of measurement: ELISA.	—

Measure

Time frame

Mood. Timepoint: At baseline and after weeks 12. Method of measurement: Beck Depression Inventory.;Serum cortisol. Timepoint: At baseline and after weeks 12. Method of measurement: ELISA.;Serum tryptophan. Timepoint: At baseline and after weeks 12. Method of measurement: ELISA.;Serum kynurenine. Timepoint: At baseline and after weeks 12. Method of measurement: ELISA.;Serum BDNF. Timepoint: At baseline and after weeks 12. Method of measurement: ELISA.

—

Secondary

Measure	Time frame
Serum hs-CRP. Timepoint: At baseline and after weeks 12. Method of measurement: ELISA.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSomaye Yosaee

Department of Nutrition, School of public Health, Iran University of Medical Sciences

s_yousai2006@yahoo.com+98 21 8670 4805

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026